Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isothipendyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.70 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.70 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.70 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.70 |
| ▸ | OPRM1 known ✓ | P35372 | 5/20 | 0.70 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.70 |
| ▸ | KCNH2 known ✓ | Q12809 | 5/20 | 0.70 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.70 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.70 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.70 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.70 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.70 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.70 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.70 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.70 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.70 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.70 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.70 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isothipendyl SCHEMBL29500369 | 1.00 | KMT2A (0.97) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Isothipendyl SCHEMBL30017997 | 0.99 | KMT2A (1.00) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Isothipendyl SCHEMBL29234 | 0.99 | KMT2A (1.00) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Isothipendyl SCHEMBL6035570 | 0.90 | KMT2A (0.79) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Isothipendyl SCHEMBL28682222 | 0.89 | KMT2A (0.81) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Isothipendyl SCHEMBL19555662 | 0.89 | KMT2A (0.81) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Promethazine SCHEMBL28860403 | 0.86 | KMT2A (0.77) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Promethazine SCHEMBL41904 | 0.85 | LMNA (1.00) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Promethazine SCHEMBL5425141 | 0.85 | LMNA (1.00) | KMT2ALMNAMAPTSMN1; SMN2HIF1A | |
| Promethazine SCHEMBL2962420 | 0.85 | LMNA (1.00) | KMT2ALMNAMAPTSMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-9492541-B2 | Phenylepherine containing dosage form | SOVEREIGN PHARMACEUTICALS, LLC (US) | 2016-11-15 | — | — | US | claimed |
| EP-0414920-B2 | AEROSOL PREPARATION FOR EXTERNAL USE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-09-27 | — | — | EP | claimed |
| EP-1696855-A1 | DERMAL DRUG DELIVERY SYSTEM | Medpharm Limited (GB) | 2006-09-06 | — | — | EP | claimed |
| US-20060130266-A1 | Dermal drug delivery system | MEDPHARM LIMITED (GB) | 2006-06-22 | — | — | US | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| US-20060057205-A1 | Phenylepherine containing dosage form | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2006-03-16 | — | — | US | claimed |
| WO-2006022996-A2 | DOSAGE FORM CONTAINING MULTIPLE DRUGS | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2006-03-02 | — | — | WO | claimed |
| WO-2005094832-A1 | COMPOSITIONS COMPRISING MELOXICAM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| EP-1418889-A2 | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMINISTRATION OF PHARMACEUTICALS AND OTHER ACTIVE COMPOUNDS | Access Pharmaceuticals, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030138490-A1 | Synthesis and uses of polymer gel nanoparticle networks | HU ZHIBING (US) | 2003-07-24 | — | — | US | claimed |
| US-6585997-B2 | Comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non- adhesive backing layer that controls residence time of the device | ACCESS PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| WO-2003022910-A1 | SYNTHESIS AND USES OF POLYMER GEL NANOPARTICLE NETWORKS | ACCESS PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| US-20030044446-A1 | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMN. OF PHARMACEUTICALS & OTHER ACTI | 2003-03-06 | — | — | US | claimed |
| WO-2003015748-A2 | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMINISTRATION OF PHARMACEUTICALS AND OTHER ACTIVE COMPOUNDS | ACCESS PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| US-6159498-A | WATER-SOLUBLE DELIVERY DEVICE FOR APPLICATION TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0414920-B1 | AEROSOL PREPARATION FOR EXTERNAL USE | TAISHO PHARMACEUTICAL CO LTD (JP) | 1997-05-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138490-A1 | Synthesis and uses of polymer gel nanoparticle networks | NCLN, PNN, TAGLN2 | CHRM2 3239/4885HTR1A 4803/4885CHRM1 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.